OSL
data caveat$16M—
OncoSil Medical
Oncology
OncoSil phosphorus-32 brachytherapy device for unresectable pancreatic cancer; TGA/CE approved
Data HealthTrials3 of 3 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$16M
Burn Rate
—
Shares Outstanding
31M
Pipeline Assets
2
Latest Insight(1)
20 Mar 2026substantial_holderChange in substantial holding from SOL
Changed·WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED (Soul Patts) AND SUBSIDIARIES·20.23%
3M Price
OSL.ASX$0.510-35.0% 3M
Low $0.475High $0.835
Pipeline Assets (2)
OncoSil (P-32)Locally advanced pancreatic cancer
Phase 2OncoSil (P-32)Pancreatic cancer (post-market)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
OncoSil (P-32)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
6 transactionsLast 90dNet Buy
Buys4+4 vs prior
Sells0
Buy Value$129k
warning2 directors bought within 30 days (03-17 – 03-17) — $129k total
$34,3652026-03-17
Substantial Holders (5%+ threshold)
6 noticesarrow_drop_upWASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED AND SUBSIDIARIES
20.23%2026-03-20
arrow_drop_upWASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED (Soul Patts) AND SUBSIDIARIES
20.23%2026-03-20
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
108 competitor trialsPhase 2+ · Non-ASX
Locally Advanced Pancreatic Cancer108 active trials
1 Ph49 Ph32 Ph2/364 Ph232 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
9 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
J Laparoendosc Adv Surg Tech A2026-04· P-32
A haplotype-layered GWAS identifies a multi-trait grain mold resistance hub on sorghum chromosome 5.
Theor Appl Genet2026-04· P-32
World J Pediatr Congenit Heart Surg2026-04· P-32
Med Teach2026-04· P-32
Catalysts (1)
Upcoming
SpeculativeremoveMed30 May 2029
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Trial data readout — OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italyopen_in_new Primary completion expected for NCT06399172. Indication: {"Locally Advanced Pancreatic Adenocarcinoma"} | data readout | Speculative | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(3)
3 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1471d
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
Pancreatic Neoplasm · Digestive System Neoplasm · Neoplasms by Site +5 more
18 Years – 90 Years
Primary endpoint Safety and tolerability of Device
Not Yet RecruitingOBSERVATIONALEnrollment stale · 692d
OncoSil
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Locally Advanced Pancreatic Adenocarcinoma
18 Years+
Primary endpoint Safety and tolerability
Ph2Active Not RecruitingEnrollment stale · 1092d
FOLFIRINOX chemotherapyOncoSil™
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Cancer
RandomizedOpen Label18 Years+
Primary endpoint Safety and Tolerability
Announcements(7)
article
substantial_holderauto_awesome
Change in substantial holding from SOL20 Mar 2026
expand_more410KB
article
substantial_holderauto_awesome
Change in substantial holding from PCG19 Mar 2026
expand_more291KB